pembrolizumab Nov 17, 2022 Biomarker Predicts Immunotherapy Benefit in Head and Neck Cancer but Commercial Path Unclear Premium Nov 17, 2022 Immunotherapy-Related Myocarditis Caused by Rogue T-Cell Attack, Study Finds Premium Nov 8, 2022 NICE Recommends Keytruda for Neoadjuvant, Adjuvant Treatment of Triple-Negative Breast Cancer Oct 27, 2022 Keytruda Revenue Climbs 20 Percent in Q3 as Merck Continues Push Into Earlier-Stage Cancer Settings Premium Oct 14, 2022 Nucleai Hopes to Engage Pharma on Next-Gen Immunotherapies With Proof-of-Concept AI-Based Biomarker Premium Oct 12, 2022 Merck Exercises Option on Moderna Cancer Vaccine Oct 4, 2022 Personalis, Duke University, Olink Collaborate on Immunotherapy Markers in Gastric Cancer Sep 1, 2022 Aston Sci. to Launch Phase II US Study of Experimental Vaccine in HER2-Low Breast Cancer Patients Jul 28, 2022 Merck's Keytruda Q2 Sales Grow 26 Percent; Firm Considers Future Impact of Medicare Price Setting Premium Jul 27, 2022 Celularity Begins Trial of NK Cell Therapy, Herceptin, Keytruda for HER2-Positive Gastric Cancer Jul 18, 2022 PMV Pharmaceuticals Studying p53 Y220C Reactivator With Merck's Keytruda in Phase I/II Trial Jul 12, 2022 NCCN Publishes First Guidelines for Pediatric Brain Cancer, Recommends Broad NGS Profiling Jul 6, 2022 Zenith Epigenetics to Explore BET Inhibitor Combinations in Multiple NCI-Sponsored Trials Jun 22, 2022 Agendia Building Validation Data on ImPrint for Guiding Neoadjuvant Immunotherapy in Breast Cancer Premium May 25, 2022 Oncotelic Gets FDA Permission to Start Phase II Trial of TGF-B Inhibitor, Keytruda in Mesothelioma May 25, 2022 NICE Recommends Keytruda, Chemo Combo for Advanced TNBC, Narrows PD-L1 Expression Threshold May 18, 2022 City of Hope, Imugene Begin Trial of Oncolytic Virus in Advanced Solid Cancers Apr 29, 2022 Merck Nabs European Approvals for Keytruda in Cervical Cancer, Biomarker-Defined Solid Tumors Apr 28, 2022 Merck Q1 Revenues Increase 50 Percent Driven by Keytruda Apr 19, 2022 PDS Biotechnology Nets $1.2M Through NJ Economic Development Program to Advance Oncology Candidates Load More Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer
